Abilify nudges $4bn US sales landmark for Otsuka
This article was originally published in Scrip
Otsuka Holdings has reported a solid set of results for the fiscal year ended 31 March, driven again by international and US growth for its flagship product Abilify (aripiprazole).
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.